Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: Experience of a paediatric infectious diseases unit

Kjöllerström, Paula; Brito, Maria João; Gouveia, Catarina; Ferreira, Gonçalo Cordeiro; Varandas, Luís

doi:10.3109/00365548.2011.564649

Cited by 22 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been studies of linezolid in children with MDR-TB showing the drug is effective, but safety issues have been reported with longer durations and higher doses, including hematologic toxicity and peripheral neuropathy (56)(57)(58). Linezolid has been recommended in children when close clinical monitoring is possible, and the WHO recommends that linezolid be included in the treatment regimens of children with confirmed or probable MDR-TB as part of the "other core second-line agents" that can be used to build a treatment regimen of at least four effective drugs (9,59).…”

Section: Linezolidmentioning

confidence: 99%

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

Harausz

Garcia-Prats

Seddon

et al. 2017

Am J Respir Crit Care Med

View full text Add to dashboard Cite

It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.

show abstract

Section: Linezolidmentioning

confidence: 99%

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

Harausz

Garcia-Prats

Seddon

et al. 2017

Am J Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…These included prospective and retrospective observational studies. Figure 1 shows how a cohort of fluoroquinoloneresistant MDR-TB patients treated with WHO group 5 drugs was assembled from 20 articles (6,(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39). The cohort consisted of 194 patients from 12 countries: 117 from four Asian regions (South Korea, China, Hong Kong, and India), 40 from five European countries (Portugal, Italy, Germany, Belgium, and Spain), 36 from two North and South American countries (the United States and Argentina), and 1 from South Africa.…”

Section: Findings and Conclusionmentioning

confidence: 99%

WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis

Chang¹,

Yew

Tam³

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

It is often necessary to include WHO group 5 drugs in the treatment of extensively drug-resistant tuberculosis (XDR-TB) and fluoroquinolone-resistant multidrug-resistant tuberculosis (MDR-TB). As clinical evidence about the use of group 5 drugs is scarce, we conducted a systematic review using published individual patient data. We searched PubMed and OvidSP through 7 April 2013 for publications in English to assemble a cohort with fluoroquinolone-resistant MDR-TB treated with group 5 drugs. Favorable outcome was defined as sputum culture conversion, cure, or treatment completion in the absence of death, default, treatment failure, or relapse. A cohort of 194 patients was assembled from 20 articles involving 12 geographical regions. In descending order of frequency, linezolid was used in treatment of 162 (84%) patients, macrolides in 84 (43%), clofazimine in 65 (34%), amoxicillin with clavulanate in 56 (29%), thioridazine in 18 (9%), carbapenem in 16 (8%), and high-dose isoniazid in 16 (8%). Cohort analysis with robust Poisson regression models and random-effects meta-analysis similarly suggested that linezolid use significantly increased the probability (95% confidence interval) of favorable outcome by 57% (10% to 124%) and 55% (10% to 121%), respectively. Defining significant associations by risk ratios > 1.2 or < 0.9, neither cohort analysis nor meta-analysis demonstrated any significant add-on benefit from the use of other group 5 drugs with respect to outcome for patients treated with linezolid, although selection bias might have led to underestimation of their effects. Our findings substantiated the use of linezolid in the treatment of XDR-TB or fluoroquinolone-resistant MDR-TB and call for further studies to evaluate the roles of other group 5 drugs.

show abstract

“…5 We present here a well-succeeded case of treatment with this drug. However, side effects have been reported, being the gastrointestinal, cutaneous and hematologic disorders the most common.…”

Section: Discussionmentioning

confidence: 93%

“…Experience in children is scarce and most data are derived from adult studies. [5][6][7][8][9][10] We describe 2 pediatric patients in whom new diagnostic approaches and multidisciplinary management of medical treatment were crucial to good clinical evolution.…”

mentioning

confidence: 99%

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Adolescent Patients

Rodrigues

Brito²,

Villar³

et al. 2014

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

The authors describe 2 pediatric patients with drug-resistant tuberculosis in whom new diagnostic and therapeutic approaches were crucial to good clinical evolution. Although there was good clinical outcome, important side effects with linezolid and amikacin occurred, namely medullary hypoplasia and neurosensorial hypoacusia, respectively. A multidisciplinary approach with close follow up was of major importance in managing these patients.

show abstract

Linezolid in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis in paediatric patients: Experience of a paediatric infectious diseases unit

Cited by 22 publications

References 9 publications

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations

WHO Group 5 Drugs and Difficult Multidrug-Resistant Tuberculosis: a Systematic Review with Cohort Analysis and Meta-Analysis

Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Adolescent Patients

Contact Info

Product

Resources

About